BSX · 10-Q · 2026Q2 · Full report
Regulatory Risk
BOSTON SCIENTIFIC CORP · 2026-08-03 · Importance 75 · Surprise 60 · In source text
The U.S. Federal Trade Commission is reviewing Boston Scientific’s proposed $14.5 billion acquisition of Penumbra. On March 16, 2026, Boston Scientific and Penumbra each received a Second Request for additional information from the FTC. The companies are responding to the request and cooperating with the FTC, and the transaction remains subject to regulatory clearances before its expected completion in the second half of 2026.
Key facts
- Boston Scientific and Penumbra each received a Second Request from the U.S. Federal Trade Commission on March 16, 2026 in connection with the FTC's review of the acquisition, and the companies are responding and working cooperatively with the FTC. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| assets | unclear | contingent | — | Boston Scientific and Penumbra each received a Second Request from the U.S. Federal Trade Commission on March 16, 2026 in connection with… |